May-16-22 02:23AM |
CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed DrugsZacks Investment Research |
May-14-22 06:30AM |
Here's the No. 1 Reason to Buy Vertex Pharmaceuticals NowThe Motley Fool |
May-13-22 11:52AM |
Why Editas Medicine's Shares Fell 28.9% This WeekThe Motley Fool |
11:45AM |
2 Stocks With 75% to 183% Upside, According to Wall StreetThe Motley Fool |
May-13-22 10:32AM |
These 5-Stock Samplers Have Gotten Whacked. And That's OKThe Motley Fool |
May-12-22 04:19AM |
Why Cathie Wood's Flagship ETF Slumped This WeekThe Motley Fool |
10:33AM |
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid CongressGlobeNewswire Inc. |
May-10-22 02:23AM |
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial DataBenzinga |
10:30AM |
CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss EstimatesZacks Investment Research |
May-09-22 05:15AM |
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research |
May-06-22 10:37AM |
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View TweakedZacks Investment Research |
May-04-22 08:00AM |
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare ConferenceGlobeNewswire Inc. |
May-02-22 06:02AM |
3 Beaten-Down Stocks That Could Deliver 5X Gains By 2030The Motley Fool |
Apr-30-22 09:05AM |
2 Biotech Stocks to Buy and Hold for 10 YearsThe Motley Fool |
Apr-28-22 10:09AM |
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022Benzinga |
09:14AM |
What 4 Analyst Ratings Have To Say About CRISPR TherapeuticsBenzinga |
Apr-27-22 09:18AM |
These 2 Stocks Carry a Lot of Risk, but Their Upside Is HugeThe Motley Fool |
Apr-22-22 02:58AM |
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?Zacks Investment Research |
Apr-19-22 06:20AM |
3 Ominous Reasons to Avoid This Biotech PioneerThe Motley Fool |
Apr-14-22 10:03AM |
M&As in Spotlight With GSK Announcement: 3 Biotechs in FocusZacks Investment Research |
08:00AM |
Is Now the Time to Bet on This Game-Changing Stock?The Motley Fool |
Apr-13-22 10:45AM |
CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030The Motley Fool |
05:52AM |
Another Nasdaq Bear Market on the Way? 3 Great Stocks to Buy AnywayThe Motley Fool |
Apr-12-22 04:01AM |
CRISPR Therapeutics Proposes New Appointment to the Board of DirectorsGlobeNewswire Inc. |
Apr-07-22 04:01AM |
CRISPR Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. |
Apr-06-22 07:47AM |
Vertex (VRTX) Stock Rallies 27% in a Year: What Lies Ahead?Zacks Investment Research |
Apr-01-22 12:17PM |
Vertex's (VRTX) Pain Candidate Meets Goal in Two StudiesZacks Investment Research |
10:45AM |
Worried About Rising Interest Rates? These 2 Growth Stocks Could HelpThe Motley Fool |
Mar-29-22 08:15AM |
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research |
Mar-26-22 01:49AM |
How to future-proof your stock investments and outperform the market at the same timeMarketWatch |
08:00AM |
3 Ultra-Popular Stocks That Could Soar 120%, 51%, and 109%, Wall Street SaysThe Motley Fool |
Mar-25-22 11:55AM |
How to future-proof your stock investments and outperform the market at the same timeMarketWatch |
Mar-23-22 08:28AM |
Vertex (VRTX) to Begin Pivotal Study on Kidney CandidateZacks Investment Research |
06:30AM |
Missed Out on Moderna? My Best Biotech Stock to Buy and HoldThe Motley Fool |
Mar-18-22 07:16AM |
3 Cathie Wood Stocks to Buy and Hold for 10 YearsThe Motley Fool |
Mar-17-22 11:30AM |
CRISPR Therapeutics AG (CRSP) Up 5.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research |
05:38AM |
BeiGene, Ltd. (BGNE) Soars 25.1%: Is Further Upside Left in the Stock?Zacks Investment Research |
Mar-16-22 12:27PM |
Who Benefits From Amazon's Stock Split?The Motley Fool |
10:37AM |
Is CRISPR Therapeutics Stock a Buy Now?The Motley Fool |
Mar-14-22 06:05AM |
3 No-Brainer Stocks to Buy With $1,000 Right NowThe Motley Fool |
Mar-11-22 07:49AM |
Why CRISPR Therapeutics Stock Soared This WeekThe Motley Fool |
12:23PM |
Intellia (NTLA) Depreciates 27% Over a Month: Here's WhyZacks Investment Research |
Mar-08-22 05:31AM |
CRISPR Therapeutics Stock Surged Today: Is It a Buy?The Motley Fool |
04:35AM |
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual MeetingGlobeNewswire Inc. |
Mar-08-22 04:18AM |
Why CRISPR Therapeutics Stock Is Soaring TodayThe Motley Fool |
Mar-03-22 06:15AM |
Can Biotech Stocks Provide Crypto-Like Growth for Your Portfolio?The Motley Fool |
Mar-01-22 10:45AM |
2 Stocks to Buy No Matter What Happens in MarchThe Motley Fool |
05:52AM |
Should You Buy Stocks Now? Here's What Warren Buffett ThinksThe Motley Fool |
Feb-16-22 11:48AM |
CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/YZacks Investment Research |
05:56AM |
3 Biotech Stocks to Buy in FebruaryThe Motley Fool |